124 related articles for article (PubMed ID: 37259807)
41. Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma.
Kolstad A; Laurell A; Jerkeman M; Grønbæk K; Elonen E; Räty R; Pedersen LB; Loft A; Bogsrud TV; Kimby E; Hansen PB; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Lehmann AK; Sundstrom C; Karjalainen-Lindsberg ML; Ralfkiaer E; Ehinger M; Delabie J; Bentzen H; Schildt J; Kostova-Aherdan K; Frederiksen H; Brown Pde N; Geisler CH;
Blood; 2014 May; 123(19):2953-9. PubMed ID: 24652994
[TBL] [Abstract][Full Text] [Related]
42. Whole genome copy number analysis in search of new prognostic biomarkers in first line treatment of mantle cell lymphoma. A study by the LYSA group.
Le Bris Y; Magrangeas F; Moreau A; Chiron D; Guérin-Charbonnel C; Theisen O; Pichon O; Canioni D; Burroni B; Maisonneuve H; Thieblemont C; Oberic L; Gyan E; Pellat-Deceunynck C; Hermine O; Delfau-Larue MH; Tessoulin B; Béné MC; Minvielle S; Le Gouill S
Hematol Oncol; 2020 Oct; 38(4):446-455. PubMed ID: 32472610
[TBL] [Abstract][Full Text] [Related]
43. Clinical laboratory validation of the MCL35 assay for molecular risk stratification of mantle cell lymphoma.
Ramsower CA; Maguire A; Robetorye RS; Feldman AL; Syrbu SI; Rosenthal AC; Rimsza LM
J Hematop; 2020 Dec; 13(4):231-238. PubMed ID: 33193905
[TBL] [Abstract][Full Text] [Related]
44. High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
Hermine O; Jiang L; Walewski J; Bosly A; Thieblemont C; Szymczyk M; Pott C; Salles G; Feugier P; Hübel K; Haioun C; Casasnovas RO; Schmidt C; Bouabdallah K; Ribrag V; Kanz L; Dürig J; Metzner B; Sibon D; Cheminant M; Burroni B; Klapper W; Hiddemann W; Unterhalt M; Hoster E; Dreyling M;
J Clin Oncol; 2023 Jan; 41(3):479-484. PubMed ID: 36469833
[No Abstract] [Full Text] [Related]
45. A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma.
Lv H; Fei Y; Li W; Wang Y; Wang J; He J; Liu X; Li L; Qiu L; Qian Z; Zhou S; Meng B; Zhai Q; Ren X; Zou D; Cai Q; Wang X; Zhang H
Hematol Oncol; 2022 Aug; 40(3):343-355. PubMed ID: 35368100
[TBL] [Abstract][Full Text] [Related]
46. Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2017 Aug; 92(8):806-813. PubMed ID: 28699667
[TBL] [Abstract][Full Text] [Related]
47. Prognostic impact of interim positron emission tomography in mantle cell lymphoma patients treated with frontline R-CHOP.
Jeon YW; O JH; Park KS; Min GJ; Park SS; Yoon JH; Eom KS; Min CK; Cho SG
Br J Haematol; 2020 Mar; 188(6):860-871. PubMed ID: 31733125
[TBL] [Abstract][Full Text] [Related]
48. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
49. Treatment patterns and outcomes of older patients with mantle cell lymphoma in an Asian population.
Yang X; Khoo LP; Chang EWY; Yang VS; Poon E; Somasundaram N; Farid M; Tang TPL; Tao M; Lim ST; Chan JY
BMC Cancer; 2021 May; 21(1):566. PubMed ID: 34001056
[TBL] [Abstract][Full Text] [Related]
50. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
51. Bendamustine and rituximab as induction therapy in both transplant-eligible and -ineligible patients with mantle cell lymphoma.
Villa D; Sehn LH; Savage KJ; Toze CL; Song K; den Brok WD; Freeman CL; Scott DW; Gerrie AS
Blood Adv; 2020 Aug; 4(15):3486-3494. PubMed ID: 32735654
[TBL] [Abstract][Full Text] [Related]
52. Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601.
Till BG; Li H; Bernstein SH; Fisher RI; Burack WR; Rimsza LM; Floyd JD; DaSilva MA; Moore DF; Pozdnyakova O; Smith SM; LeBlanc M; Friedberg JW
Br J Haematol; 2016 Jan; 172(2):208-18. PubMed ID: 26492567
[TBL] [Abstract][Full Text] [Related]
53. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.
Hoster E; Dreyling M; Klapper W; Gisselbrecht C; van Hoof A; Kluin-Nelemans HC; Pfreundschuh M; Reiser M; Metzner B; Einsele H; Peter N; Jung W; Wörmann B; Ludwig WD; Dührsen U; Eimermacher H; Wandt H; Hasford J; Hiddemann W; Unterhalt M; ;
Blood; 2008 Jan; 111(2):558-65. PubMed ID: 17962512
[TBL] [Abstract][Full Text] [Related]
54. VcR-CVAD Induction Chemotherapy Followed by Maintenance Rituximab Produces Durable Remissions in Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE; Carmichael LL; Kim K; Peterson C; Yang DT; Traynor AM; Werndli JE; Huie MS; McFarland TA; Volk M; Blank J; Callander NS; Longo WL; Kahl BS
Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e61-e67. PubMed ID: 29191715
[TBL] [Abstract][Full Text] [Related]
55. Prognostic relevance of clinical risk factors in mantle cell lymphoma.
Hoster E
Semin Hematol; 2011 Jul; 48(3):185-8. PubMed ID: 21782060
[TBL] [Abstract][Full Text] [Related]
56. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
57. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
Mato AR; Svoboda J; Feldman T; Zielonka T; Agress H; Panush D; Miller M; Toth P; Lizotte PM; Nasta S; Goldberg S; Chong E; Schuster S; Pecora AL; Goy A
Cancer; 2012 Jul; 118(14):3565-70. PubMed ID: 22180256
[TBL] [Abstract][Full Text] [Related]
58. [
Vergote VKJ; Verhoef G; Janssens A; Woei-A-Jin FJSH; Laenen A; Tousseyn T; Dierickx D; Deroose CM
Leuk Lymphoma; 2023 Jan; 64(1):161-170. PubMed ID: 36223113
[TBL] [Abstract][Full Text] [Related]
59. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network.
Dreyling M; Lenz G; Hoster E; Van Hoof A; Gisselbrecht C; Schmits R; Metzner B; Truemper L; Reiser M; Steinhauer H; Boiron JM; Boogaerts MA; Aldaoud A; Silingardi V; Kluin-Nelemans HC; Hasford J; Parwaresch R; Unterhalt M; Hiddemann W
Blood; 2005 Apr; 105(7):2677-84. PubMed ID: 15591112
[TBL] [Abstract][Full Text] [Related]
60. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
